Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chubb
Merck
Chinese Patent Office
Accenture
Cipla
Novartis
Federal Trade Commission
US Army
Johnson and Johnson

Generated: October 24, 2017

DrugPatentWatch Database Preview

ACTONEL Drug Profile

« Back to Dashboard

What is the patent landscape for Actonel, and what generic Actonel alternatives are available?

Actonel is a drug marketed by Apil and Warner Chilcott and is included in two NDAs. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and ninety-eight patent family members in forty-nine countries and nine supplementary protection certificates in five countries.

The generic ingredient in ACTONEL is calcium carbonate; risedronate sodium. There are two hundred and seventy drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.

Summary for Tradename: ACTONEL

US Patents:7
Applicants:2
NDAs:2
Suppliers / Packagers: see list4
Bulk Api Vendors: see list101
Clinical Trials: see list31
Patent Applications: see list3,389
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ACTONEL at DailyMed

Pharmacology for Tradename: ACTONEL

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-002Apr 14, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Warner Chilcott
ACTONEL WITH CALCIUM (COPACKAGED)
calcium carbonate; risedronate sodium
TABLET, TABLET;ORAL021823-001Aug 12, 2005DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-004Apr 16, 2007DISCNYesNo► Subscribe► SubscribeY► Subscribe
Warner Chilcott
ACTONEL WITH CALCIUM (COPACKAGED)
calcium carbonate; risedronate sodium
TABLET, TABLET;ORAL021823-001Aug 12, 2005DISCNYesNo► Subscribe► SubscribeY► Subscribe
Warner Chilcott
ACTONEL WITH CALCIUM (COPACKAGED)
calcium carbonate; risedronate sodium
TABLET, TABLET;ORAL021823-001Aug 12, 2005DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-001Mar 27, 1998ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ACTONEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-005Apr 22, 2008► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-002Apr 14, 2000► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-004Apr 16, 2007► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-004Apr 16, 2007► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-001Mar 27, 1998► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-003May 25, 2002► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-002Apr 14, 2000► Subscribe► Subscribe
Apil
ACTONEL
risedronate sodium
TABLET;ORAL020835-001Mar 27, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ACTONEL

Drugname Dosage Strength RLD Submissiondate
risedronate sodiumTablets150 mgActonel8/12/2008
risedronate sodium with calcium carbonateTablets35 mg; 500 mgActonel with Calcium12/18/2007
risedronate sodiumTablets75 mgActonel9/10/2007
risedronate sodiumTablets5 mg, 30 mg and 35 mgActonel4/23/2004

Non-Orange Book Patents for Tradename: ACTONEL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,225,294 Method for inhibiting bone resorption► Subscribe
6,569,460 Film-coated tablet for improved upper gastrointestinal tract safety► Subscribe
7,410,957Method of treatment using bisphosphonic acid► Subscribe
6,544,967 Method for inhibiting bone resorption► Subscribe
6,333,316 Method for inhibiting bone resorption► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ACTONEL

Country Document Number Estimated Expiration
Denmark1506041► Subscribe
Israel205262► Subscribe
Germany122006000009► Subscribe
Australia2003229770► Subscribe
Eurasian Patent Organization004544► Subscribe
Japan2005522526► Subscribe
Austria209037► Subscribe
Canada2294595► Subscribe
Japan2002504112► Subscribe
Bulgaria66282► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ACTONEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1175904/01Switzerland► SubscribeFORMER OWNER: SCHERING CORPORATION, US
00292Netherlands► SubscribePRODUCT NAME: ALENDRONINE ZUUR, BIJ VOORKEUR MET MONONATRIUMZOUT IN HET BIJZONDER HET MONONATRIUM TRIHYDRAATZOUT, EN COLECALCIFEROL, WAARIN 70MG ALENDRONINEZUUR AANWEZIG IS, GEBASSERD OP HET GEWICHT VAN ALENDRONINE; REGISTRATION NO/DATE: EU/1/05/310/001-005 20050824
2006 00005Denmark► Subscribe
2006002,C0998292Lithuania► SubscribePRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
364Luxembourg► Subscribe91364, EXPIRES: 20200826
222Luxembourg► Subscribe91222, EXPIRES: 20200824
2007007Lithuania► SubscribePRODUCT NAME: ACIDUM ALENDRONICUM NATRIUM, COLECALCIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001 2005 08 24 EU/1/05/310/002 2005 08 24 EU/1/05/310/003 2005 08 24 EU/1/05/310/004 2005 08 24 EU/1/05/310/00 20050824
2006002Lithuania► SubscribePRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
2007 00045Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Novartis
AstraZeneca
Citi
Cerilliant
Moodys
QuintilesIMS
Boehringer Ingelheim
Teva
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot